76322-09-3

Basic information

• Product Name: ETHYL 2-[(1-FORMYL-2-NAPHTHYL)OXY]ACETATE
• Synonyms: AKOS AU36-M53;ETHYL 2-[(1-FORMYL-2-NAPHTHYL)OXY]ACETATE
• CAS NO: 76322-09-3
• Molecular Formula: C₁₅H₁₄O₄
• Molecular Weight: 258.27
• Mol File: 76322-09-3.mol

Chemical Properties

• Melting Point: 90-92°C
• Boiling Point: 419.9°C at 760 mmHg
• Flash Point: 187.7°C
• Appearance: /
• Density: 1.216g/cm³
• Vapor Pressure: 2.93E-07mmHg at 25°C
• Refractive Index: 1.606
• CAS DataBase Reference: ETHYL 2-[(1-FORMYL-2-NAPHTHYL)OXY]ACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 2-[(1-FORMYL-2-NAPHTHYL)OXY]ACETATE(76322-09-3)
• EPA Substance Registry System: ETHYL 2-[(1-FORMYL-2-NAPHTHYL)OXY]ACETATE(76322-09-3)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 76322-09-3(Hazardous Substances Data)

Usage

Uses

Used in Fragrance Industry:
ETHYL 2-[(1-FORMYL-2-NAPHTHYL)OXY]ACETATE is used as a fragrance ingredient for its aromatic properties, contributing to the creation of various scents in perfumes, colognes, and other scented products.
Used in Flavoring Industry:
In the flavoring industry, ETHYL 2-[(1-FORMYL-2-NAPHTHYL)OXY]ACETATE is used as a flavoring agent to enhance the taste and aroma of food and beverages, providing a unique flavor profile.
Used in Pharmaceutical Industry:
ETHYL 2-[(1-FORMYL-2-NAPHTHYL)OXY]ACETATE is utilized as an active pharmaceutical ingredient or as an intermediate in the synthesis of various drugs, thanks to its unique molecular structure and reactivity.
Used in Chemical Research:
In the field of chemical research, ETHYL 2-[(1-FORMYL-2-NAPHTHYL)OXY]ACETATE serves as a valuable compound for the synthesis of organic compounds, aiding in the development of new chemical entities and understanding reaction mechanisms.
Used as a Solvent in Chemical Processes:
ETHYL 2-[(1-FORMYL-2-NAPHTHYL)OXY]ACETATE is employed as a solvent in various chemical processes, facilitating reactions and improving the efficiency of industrial chemical production.

InChI:InChI=1/C15H14O4/c1-2-18-15(17)10-19-14-8-7-11-5-3-4-6-12(11)13(14)9-16/h3-9H,2,10H2,1H3

Upstream product

• 105-36-2 ethyl bromoacetate 
• 708-06-5 2-hydroxynaphthalene-1-carbaldehyde 
• 105-39-5 chloroacetic acid ethyl ester 

Downstream Products

• 232-95-1 naphtho[2,1-b]furan 
• 260784-21-2 5-(2-carboxymethoxy-1-naphthylmethylene)-4-oxo-2-thioxothiazolidine 
• 5656-67-7 acide naphtho<2,1-b>furanne carboxilique 

Relevant articles and documents

Novel Fluorometric Turn On Detection of Aluminum by Chalcone-Based Chemosensor in Aqueous Phase

A novel, 100% water-soluble chalcone based chemosensing receptor {1-[3-(2-Hydroxy-phenyl)-3-oxo-propenyl]-naphthalen-2-yloxy}-acetic acid, L was synthesized and characterized. The receptor L is designed based on the chelation enhanced fluorescence (CHEF) mechanism. The chemosensing properties of L were evaluated by UV–vis and fluorescence spectrometric methods. It exhibits highly selective recognition ability towards aluminum ions in water over other metal ions. The binding stoichiometry of L? Al3+ complex is 2:1 by means of Job’s plot and the detection limit is 5.66 × 10? 8 M.

Novel reaction-based chemosensor for Al3+ detection using hybrid framework of chalcone-coumarin in aqueous phase and its anticancer activity

A new water-soluble chemosensor (L) made up by chalcone-coumarin hybrid framework was synthesized and the photophysical properties of probe L towards heavy metal ions were observed by naked-eye along with UV-vis and NMR spectroscopic techniques. The newly obtained chemosensor L showed an apparent colour change from yellow to cyan due to the presence of a new hump at 610.2 nm in UV-vis spectrum which can be ascribed to the affinity of L towards the aluminium Al3+ ion. The receptor L displays excellent selectivity and sensitivity towards Al3+ ion with the detection limit of 2.21 × 10?5 M. The stoichiometric ratio and association constant for the L-Al3+ complex are 2:1 and 5.91 M-2, respectively. The IC50 value of 15.38 μM as shown by probe L indicates that it exhibits strong anticancer properties.

Purple acid phosphatase inhibitors as leads for osteoporosis chemotherapeutics

Purple acid phosphatases (PAPs) are metalloenzymes that catalyse the hydrolysis of phosphate esters under acidic conditions. Their active site contains a Fe(III)Fe(II) metal centre in mammals and a Fe(III)Zn(II) or Fe(III)Mn(II) metal centre in plants. In humans, elevated PAP levels in serum strongly correlate with the progression of osteoporosis and metabolic bone malignancies, which make PAP a target suitable for the development of chemotherapeutics to combat bone ailments. Due to difficulties in obtaining the human enzyme, the corresponding enzymes from red kidney bean and pig have been used previously to develop specific PAP inhibitors. Here, existing lead compounds were further elaborated to create a series of inhibitors with Ki values as low as ～30 μM. The inhibition constants of these compounds were of comparable magnitude for pig and red kidney bean PAPs, indicating that relevant binding interactions are conserved. The crystal structure of red kidney bean PAP in complex with the most potent inhibitor in this series, compound 4f, was solved to 2.40 ? resolution. This inhibitor coordinates directly to the binuclear metal centre in the active site as expected based on its competitive mode of inhibition. Docking simulations predict that this compound binds to human PAP in a similar mode. This study presents the first example of a PAP structure in complex with an inhibitor that is of relevance to the development of anti-osteoporotic chemotherapeutics.

Synthesis and aldose reductase inhibitory activity of a new series of 5- [[2-(ω-carboxyalkoxy)aryl]methylene]-4-oxo-2-thioxothiazolidine derivatives

A new series of 5-[[2-(ω-carboxyalkoxy)aryl]methylene]-4-oxo-2- thioxothiazolidine derivatives was synthesized and evaluated for their potency as aldose reductase inhibitors (ARIs). Their activities were examined in terms of their inhibitory effect on rat lens aldose reductase in vitro and in terms of the preventive effect on sorbitol accumulation in the sciatic nerve of streptozotocin (STZ)-induced diabetic rats in vivo. Of these compounds, some of the naphthylmethylene thiazolidine derivatives were comparable to Zenarestat in the inhibitory potency in vitro and in vivo. In particular, compound 30 was 1.5 times more potent than Zenarestat in the in vivo activity, and had an adequate potency for clinical development.